McKesson Corporation (MCK)
3 Reasons Growth Investors Will Love McKesson (MCK)
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation (MCK) CFO Britt Vitalone Hosts BofA Securities 2025 Healthcare Conference (Transcript)
McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson: Spinoff Of Medical-Surgical Solutions Is A Positive, Strong Buy
I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8% adj. EPS growth, largely driven by strong demand for GLP-1 products, which now represent 12% of total revenue. The company's global supply chain flexibility and non-discretionary drug pricing render it largely immune to tariff uncertainties, ensuring stable future growth.
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Corporation (MCK) Q4 2025 Earnings Call Transcript
McKesson Corporation (NYSE:MCK ) Q4 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Tyler - Chief Executive Officer Britt Vitalone - Chief Financial Officer Jeni Dominguez - VP of Investor Relations Conference Call Participants Kevin Caliendo - UBS Lisa Gill - JP Morgan Allen Lutz - Bank of America Eric Percher - Nephron Research Stephen Baxter - Wells Fargo Daniel Grosslight - Citi Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Charles Rhyee - TD Cowen Operator Presentation Operator Welcome to McKesson's Fourth Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded.
Here's What Key Metrics Tell Us About McKesson (MCK) Q4 Earnings
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Tops Q4 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.81 per share. This compares to earnings of $6.18 per share a year ago.
McKesson to Spin Off Medical-Surgical Company
The pharmaceutical distributor said the new company would be a differentiated medical surgical supply and solutions business.
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
